Ensign Peak Advisors
KNSA icon

Ensign Peak Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ensign Peak Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66,443
Closed -$1.17M – 1735
2023
Q4 		$1.17M Hold
66,443
– – ﹤0.01% 1254
2023
Q3 		$1.15M Hold
66,443
– – ﹤0.01% 1085
2023
Q2 		$936K Hold
66,443
– – ﹤0.01% 1318
2023
Q1 		$715K Hold
66,443
– – ﹤0.01% 1496
2022
Q4 		$995K Sell
66,443
-11,310
-15% -$165K ﹤0.01% 1165
2022
Q3 		$998K Buy
77,753
+26,959
+53% +$307K ﹤0.01% 1064
2022
Q2 		$492K Sell
50,794
-1,946
-4% -$18.2K ﹤0.01% 1469
2022
Q1 		$524K Hold
52,740
– – ﹤0.01% 1537
2021
Q4 		$621K Sell
52,740
-21,073
-29% -$259K ﹤0.01% 1533
2021
Q3 		$841K Buy
73,813
+20,688
+39% +$269K ﹤0.01% 1492
2021
Q2 		$740K Hold
53,125
– – ﹤0.01% 1515
2021
Q1 		$983K Hold
53,125
– – ﹤0.01% 1431
2020
Q4 		$939K Buy
53,125
+26,916
+103% +$473K ﹤0.01% 1423
2020
Q3 		$402K Buy
26,209
+17,857
+214% +$335K ﹤0.01% 1582
2020
Q2 		$213K Buy
+8,352
New +$174K ﹤0.01% 1572

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's KNSA Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 66,443 shares — an estimated $1.17M sold.

Ensign Peak Advisors first reported a position in KNSA in Q2 2020 and held it in 15 quarters. The position peaked at $1.17M in Q4 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 66,443 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $1.17M.
  • Ensign Peak Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • Ensign Peak Advisors's Kiniksa Pharmaceuticals position peaked at $1.17M in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.